Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Bevenopran (Primary)
- Indications Constipation
- Focus Therapeutic Use
- Sponsors Adolor Corporation; Cubist Pharmaceuticals
- 22 May 2012 Results presented at the Digestive Disease Week 2012.
- 19 May 2012 Results presented at the 31st Annual Scientific Meeting of the American Pain Society.
- 14 May 2012 Results will be presented at the Annual Scientific Meeting of the American Pain Society (APS) in May 2012.